Symptoms and General Pathology

All Conditions

Infections

Respiratory Tract (Lung and Bronchial) Diseases

Blood and Lymph Conditions

Nervous System Diseases

Immune System Diseases

Neoplasms

Rare Diseases

Syndrome

COVID-19

Thrombocytopenia

Guillain-Barre Syndrome

Encephalomyelitis

Myelitis

Myelitis, Transverse

Encephalomyelitis, Acute Disseminated

Communicable Diseases

Blood Platelet Disorders

Hematologic Diseases

Cytopenia

Central Nervous System Infections

Central Nervous System Diseases

Neuroinflammatory Diseases

Polyradiculoneuropathy

Autoimmune Diseases

Autoimmune Diseases of the Nervous System

Demyelinating Diseases

Polyneuropathies

Peripheral Nervous System Diseases

Neuromuscular Diseases

Post-Infectious Disorders

Chronic Disease

Disease Attributes

Spinal Cord Diseases

Paraneoplastic Syndromes

Paraneoplastic Syndromes, Nervous System

Nervous System Neoplasms

Demyelinating Autoimmune Diseases, CNS

Neurodegenerative Diseases

Leukoencephalopathies

Brain Diseases

Acute Graft Versus Host Disease

Transverse Myelitis

Acute Disseminated Encephalomyelitis

Chronic Graft Versus Host Disease

All Drugs and Chemicals

Vaccines

Patrícia de Oliveira, MD

This protocol proposes to investigate genetic factors that may be involved in the pathogenesis of adverse events of interest with selected covid-19 vaccines: vaccine-induced immune thrombotic thrombocytopenia, and neurological adverse events, such as Guillain-Barré syndrome, acute disseminated encephalomyelitis and transverse myelitis, with the intention of identifying useful biomarkers in identifying people at higher risk, thus reducing the occurrence of these serious adverse events (SAE).

Participants higher than 5 years old with no maximum age limit and both sexes, who had a serious adverse event after vaccination against Covid-19, such as Guillain-Barré syndrome, vaccine-induced immune thrombotic thrombocytopenia, transverse myelitis and Acute disseminated encephalomyelitis. Parents, siblings and/or sons of cases with SAE will have biological samples collected and stored; depending on the result of the study, they may have their samples analyzed later.

Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil

Identify if any genetic marker is envolved in the serious adverse event pathogenesis induced by covid-19 vaccination.

Oswaldo Cruz Foundation

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

Eye Diseases

Multiple Sclerosis

Sclerosis

Neuromyelitis Optica

Neuritis

Optic Neuritis

Optic Nerve Diseases

Cranial Nerve Diseases

Neuromyelitis Optica Spectrum Disorder

Benjamin Greenberg, M.D., M.H.S.

To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls. Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.

Biobank For MS And Other Demyelinating Diseases

Large-scale, Multi-disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases

Accelerated Cure Project for Multiple Sclerosis

Behaviors and Mental Disorders

Diseases and Abnormalities at or Before Birth

Mental Disorders

Problem Behavior

Diffuse Cerebral Sclerosis of Schilder

Tuberous Sclerosis

Tumefactive Multiple Sclerosis

Tuberous Sclerosis Complex

Anti-Inflammatory Agents

Antineoplastic Agents

Antiemetics

Neuroprotective Agents

Gastrointestinal Agents

Prednisolone

Methylprednisolone

Methylprednisolone Acetate

Methylprednisolone Hemisuccinate

Prednisolone acetate

Prednisolone hemisuccinate

Prednisolone phosphate

Plasma exchange

Brian G. Weinshenker

OBJECTIVES:

I. Evaluate the effectiveness of plasma exchange in the treatment of acute severe attacks of inflammatory demyelinating disease in patients who have failed intravenous steroid therapy.

PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by disease type; each stratum is randomized separately.

The first group of patients receives a true plasma exchange using continuous-flow centrifugation with serum albumin and crystalloid replacement every 2 days for a total of 7 exchanges.

The second group receives a sham plasma exchange with no centrifugation every 2 days for a total of 7 exchanges.

Patients cross to the alternate therapy if there is less than a moderate improvement by day 14. The treatment decision is based on a blinded neurologic assessment.

Concurrent corticosteroids and other immunosuppressants, and high-dose barbiturates are not allowed.

Patients are followed at 1 and 6 months after the last exchange.

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone

Mayo Clinic

National Institute of Neurological Disorders and Stroke (NINDS)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil	NCT05630313	Vaccine-induced... Guillain-Barre ... Acute Dissemina... Transverse Myel...		5 Years -	The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Biobank For MS And Other Demyelinating Diseases	NCT00445367	Multiple Sclero... Transverse Myel... Neuromyelitis O... Acute Dissemina... Optic Neuritis		-	Accelerated Cure Project for Multiple Sclerosis
Biobank For MS And Other Demyelinating Diseases	NCT00445367	Multiple Sclero... Transverse Myel... Neuromyelitis O... Acute Dissemina... Optic Neuritis		-	Accelerated Cure Project for Multiple Sclerosis
Biobank For MS And Other Demyelinating Diseases	NCT00445367	Multiple Sclero... Transverse Myel... Neuromyelitis O... Acute Dissemina... Optic Neuritis		-	Accelerated Cure Project for Multiple Sclerosis
Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone	NCT00004645	Acute Dissemina... Devic's Syndrom... Marburg's Varia... Balo's Concentr... Acute Transvers...	Plasma exchange	18 Years - 60 Years	Office of Rare Diseases (ORD)

Spots Global Cancer Trial Database for acute disseminated encephalomyelitis